Press Releases

Hundreds of Alzheimer’s Advocates Urge CMS to Support Coverage of Innovative Diagnostic Scans

August 2, 2013

Hundreds of Alzheimer’s Advocates Urge CMS to Support Coverage of Innovative Diagnostic Scans

Safe and effective PET beta-amyloid scans will allow doctors to advise patients on the proper course of care and speed clinical trials

WASHINGTON, DC – Nearly 350 Alzheimer’s advocates submitted comments to the Centers for Medicare & Medicaid Services (CMS) this week, urging the agency to provide coverage for a tool able to more precisely diagnose patients being evaluated for dementia.

ResearchersAgainstAlzheimer’s Applauds Senate Committee Approval of $84 Million Increase in Funding for NIA

July 12, 2013

ResearchersAgainstAlzheimer’s Applauds Senate Appropriations Committee Approval of $84 Million Increase in Funding for NIA Alzheimer’s Research and $20 Million for Alzheimer’s Services and Supports

Researchers Call for More Rapid Growth in Research Funding to Achieve National Goal of Stopping Alzheimer’s by 2025

USAgainstAlzheimer’s Applauds Senate Committee Approval of $84 Million Increase in Funding for NIA

July 12, 2013

USAgainstAlzheimer’s Applauds Senate Appropriations Committee Approval of $84 Million Increase in Funding for NIA Alzheimer’s Research and $20 Million for Alzheimer’s Services and Support

USAgainstAlzheimer's Disappointed with Medicare Agency’s Proposal on PET Amyloid Scans

July 9, 2013

USAgainstAlzheimer’s Disappointed with Medicare Agency’s Proposal to Impose Additional Barriers to PET Amyloid Scan Diagnostic Technology

Decision would limit access to promising diagnostic tool for thousands of Alzheimer’s and dementia patients

The Global CEO Initiative on Alzheimer’s Announces Open Science Research Challenge at White House

June 20, 2013

The Global CEO Initiative on Alzheimer’s Announces Innovative Open Science Research Challenge at White House

Big Data Challenge will promote the use of crowdsourcing in an effort to spur rapid innovation in the fight against Alzheimer’s

Why 2020?

USAgainstAlzheimer’s has retained its goal of stopping Alzheimer’s by 2020 rather than endorsing the goal of the National Plan to Address Alzheimer’s Disease that calls for preventing and effectively treating the disease by 2025. While we support the national plan and its goals, we believe, as most every family touched by Alzheimer’s disease believes, that preventing and effectively treating Alzheimer's by 2025 is simply too long a wait for concrete progress. There are promising avenues of drug discovery and development that will, if successful, deliver a means of slowing or deferring Alzheimer's symptoms by 2020. By voicing the urgency felt by so many families, we will pressure researchers and industry to do all in their power to make that happen.